2
Dec
2016

21st Century Cures Rolls Thru House, Price Poised to Gut Obamacare, and Bluebird Soars

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

RevMed Nails RAS, Lilly Acquires CrossBridge, & IPOs Line Up
Gilead’s Deal Streak, Neurocrine Grows, & Stipple & Sidewinder Megarounds
Lilly Buys Centessa, Takeda & Alumis Tyk2 Showdown, & Blackstone’s Megafund
Merck Snaps Up New Cancer Drug, Denali Grows Up, & Gilead’s TCE Wager